Navigation Links
Boston Scientific Welcomes House Passage of National Pain Care Policy Act
Date:3/31/2009

xpressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (of
'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces New Initiatives to Increase Shareholder Value
7. Boston Scientific Announces Additions to Clinical Sciences Organization
8. Boston University School of Medicine physician receives award from AATOD
9. Boston Scientific Announces Verdict in Cordis Litigation
10. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
11. Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic Medical Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, ... InstantQuote ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage ... designed to help India Network members make an informed decision regarding the care ...
(Date:8/31/2015)... , ... August 31, 2015 , ... The Lisle family ... Partner William Scott has been nominated by his peers to earn a “Leading Lawyers” ... five percent of attorneys in the state of Illinois. The nomination process is based ...
(Date:8/31/2015)... ... August 31, 2015 , ... The ... event geared to patients and family members, medical professionals, and researchers, covering a ... experts. The conference is a collaborative effort between the Mesothelioma Applied Research ...
(Date:8/31/2015)... ... 2015 , ... CareSource, a nonprofit Ohio-based health plan, has ... Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications and media ... contributed to the company’s rapid growth. As the CareSource business model expands to ...
(Date:8/31/2015)... ... 2015 , ... Coast Dental Vista is celebrating its recent grand ... 3 p.m. near Albertsons in the Foothill Center, located at 1279 E. Vista Way. ... Dr. Jay Lopp. Call (760) 208-2518 for more details or stop by on September ...
Breaking Medicine News(10 mins):Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3
... & Infants Hospital of Rhode Island recently received a ... private foundation created by CVS Caremark Corporation, whose mission ... community involvement initiatives in CVS Caremark communities. Women & ... pool of 660 applicants to receive an individual or ...
... Graduations are a celebration of achievement and growth, but ... of exposure to harmful bacteria? A team of researchers ... examined the risk of acquiring pathogenic bacteria such as ... through shaking hands at graduation ceremonies across Maryland. A ...
... involved in regulating cholesterol in the bloodstream also appears to ... in a substantial number of cases of their infertility, a ... Hopkins group has also developed a simple blood test for ... gene (SCARB1) but emphasized there is no approved therapy yet ...
... work wonders against malignancies, but sometimes tumors become resistant ... Medical researchers would like to find ways of counteracting ... how it happens. New findings by Fox Chase Cancer ... Mrp7), as being intimately involved in resistance to certain ...
... research has found that lesbian, gay, bisexual, and transgender ... in middle and high school report impaired health and ... that require medical care, sexually transmitted diseases (STDs) and ... to examine the relationship between school victimization during adolescence ...
... advanced prostate cancer suggest they can be good candidates ... found a 20-year survival rate for 80 percent of ... the prostate, known as cT3 prostate cancer, and treated ... gland. Previously, patients found to have cT3 prostate cancer ...
Cached Medicine News:Health News:Women & Infants receives support from CVS Caremark Charitable Trust 2Health News:Graduation contamination 2Health News:Gene variation linked to infertility in women, study finds 2Health News:Gene variation linked to infertility in women, study finds 3Health News:Abcc10 may be effective in extending the effectiveness of anticancer drugs 2Health News:Abcc10 may be effective in extending the effectiveness of anticancer drugs 3Health News:School bullying, violence against LGBT youth linked to risk of suicide, HIV infection 2Health News:School bullying, violence against LGBT youth linked to risk of suicide, HIV infection 3
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
... Splint is constructed of a durable heat moldable ... flexor tendons of the hand and fingers from ... in the later stages of the healing process. ... hand and positions the wrist at 30° of ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
... FoamWrap Finger Trappers are ideal for ... restore finger motion. Finger Trappers' non-slip foam ... place the fingers in traction. These are ... size. Sold in packages of 5 and ...
... physiological causes of minor knee pain like ... in concert with the motion of the ... and patellar tendon and assisting in the ... plastic support with high density foam padding ...
Medicine Products: